Evotec to hire across all sites with new €90m Novo investment

By Dani Bancroft contact

- Last updated on GMT

Evotec to hire across all sites with new €90m Novo investment
Novo A/S is buying an additional €90m of shares in Evotec AG to accelerate and expand the German CRO’s outsourcing services.

Werner Lanthaler, CEO of Evotec,​ told Outsourcing-Pharma the €90m ($96m) investment will be “used for strategic growth of what we're doing, and to expand innovation projects within Evotec's R&D.”

This includes hiring of new staff and buying new equipment across all of Evotec’s sites, he added.

In particular, the firm’s 20 or so Cure X and Target X initiatives will be addressed, which span a range of indications from neurological to metabolic disease.

Lanthaler explained: “These initiatives are really academic translation. For example, we have a research partnership on neurological disease with Harvard, and another partnership with Yale.”

Novo A/S is the holding company in the Danish Novo Group, a family of independent companies owned by the Novo Nordisk Foundation.

Michael Shalmi, Managing Director of Large Investment at Novo commented “Supporting companies [like Evotec] provides more efficient solutions for the rapidly changing value chain in drug discovery and development.”

Multiple developments

Evotec has made several acquisitions and investments over the past six months, such as recently buying​ the UK-based ADMET services provider Cyprotex plc.

In January, the firm also launched​ a Toronto, Canada-based drug discovery company with MaRS Innovation, named Fibrocor Therapeutics LP.

Other deals the CRO made last month include with a German virtual biotech startup​ working on liver diseases, and a Japanese firm​ using ion channels for drug discovery.

“I think [Novo] went through Evotec’s business model, understood the combination of innovation and our highly innovative platform, and made a strategic move,” ​Lanthaler concluded.

With this investment, the Novo group now owns 8.9% of Evotec.

 

(Image: iStock/RomoloTavani)

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers